Tag Archive for: TSG-6

Link Biologics strengthens IP position for Link_TSG6 with US patent Notice of Allowance and University of Manchester IP assignment

/in

Secures long‑term ownership and protection of Link_TSG6, strengthening its global IP position in key markets De‑risks development and enhances long‑term value, supporting advancement towards clinical development London, UK – 6 May 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies that have a unique combination of anti-inflammatory, tissue-protective and […]

Read more

Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline

/in

Dr Martin brings over two decades of leadership in translational science, drug discovery and biotech strategy and entrepreneurship Strengthens Link’s position as it advances its proprietary TSG-6-based therapeutic pipeline towards the clinic  London, UK – 24 February 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies, that have a unique […]

Read more
© Optimum Strategic Communications.